{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:51:53Z","timestamp":1764251513104},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejphar.2017.12.040","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T07:55:59Z","timestamp":1513756559000},"page":"206-216","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis"],"prefix":"10.1016","volume":"820","author":[{"given":"Werner","family":"H\u00f6llriegl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randolf J.","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"H\u00f6barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schinagl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick W.K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wolfsegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marietta","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Muchitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Scheiflinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Glantschnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.12.040_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00467-016-3404-7","article-title":"Innate and adaptive immunity in experimental glomerulonephritis: a pathfinder tale","volume":"32","author":"Artinger","year":"2017","journal-title":"Pediatr. Nephrol."},{"unstructured":"Bornkamp, B., Pinheiro, J., Bretz, F., 2016. DoseFinding: Planning and Analyzing Dose Finding Experiments. R Package Version 0.9-15. URL: \u3008http:\/\/CRAN.R-project.org\/package = DoseFinding\u3009.","key":"10.1016\/j.ejphar.2017.12.040_bib2"},{"key":"10.1016\/j.ejphar.2017.12.040_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fimmu.2016.00008","article-title":"Macrophage migration inhibitory factor in clinical kidney disease","volume":"7","author":"Bruchfeld","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib4","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1084\/jem.179.6.1895","article-title":"The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor","volume":"179","author":"Calandra","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2017.12.040_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davis","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2017.12.040_bib6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1681\/ASN.2015020149","article-title":"Macrophage migration inhibitory factor mediates proliferative GN via CD74","volume":"27","author":"Djudjaj","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","article-title":"Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies","volume":"52","author":"Dostalek","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2017.12.040_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1954.tb00159.x","article-title":"Some problems in interval estimation","volume":"16","author":"Fieller","year":"1954","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.ejphar.2017.12.040_bib9","first-page":"268","article-title":"Macrophage migration inhibitory factor in systemic lupus erythematosus","volume":"31","author":"Foote","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.clim.2007.05.007","article-title":"Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis","volume":"124","author":"Fu","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/187152807781696455","article-title":"Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases","volume":"6","author":"Hoi","year":"2007","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.ejphar.2017.12.040_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar3656","article-title":"Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients","volume":"14","author":"Houssiau","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejphar.2017.12.040_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000368587","article-title":"Biologic therapy in lupus nephritis","volume":"128","author":"Houssiau","year":"2014","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.ejphar.2017.12.040_bib14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ndt\/16.3.518","article-title":"Prevention and treatment of experimental crescentic glomerulonephritis by tumor necrosis factor-alpha","volume":"16","author":"Karkar","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2017.12.040_bib15","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1074\/jbc.M111.329664","article-title":"Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the \u03b2-sheet structure of MIF","volume":"287","author":"Kerschbaumer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2017.12.040_bib16","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1523-1755.2005.00279.x","article-title":"Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis","volume":"67","author":"Khan","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2017.12.040_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nri3523","article-title":"The immune system and kidney disease: basic concepts and clinical implications","volume":"13","author":"Kurts","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib18","first-page":"1119","article-title":"De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis","volume":"149","author":"Lan","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib19","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.185.8.1455","article-title":"The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat","volume":"185","author":"Lan","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2017.12.040_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1523-1755.2000.00869.x","article-title":"Expression of macrophage migration inhibitory factor in human glomerulonephritis","volume":"57","author":"Lan","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2017.12.040_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2015.00577","article-title":"MIF: implications in the pathoetiology of systemic lupus erythematosus","volume":"6","author":"Lang","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4049\/jimmunol.1001767","article-title":"A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB\/NZW F1 and MRL\/lpr mice","volume":"186","author":"Leng","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14728222.7.2.153","article-title":"Macrophage migration inhibitory factor","volume":"7","author":"Lolis","year":"2003","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejphar.2017.12.040_bib24","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1681\/ASN.2016040415","article-title":"Current and emerging therapies for lupus nephritis","volume":"27","author":"Parikh","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib25","series-title":"Arthritis and Allied Conditions","first-page":"1523","article-title":"Systemic lupus erythematosus: pathogenesis","author":"Peterson","year":"2005"},{"year":"2016","author":"R Development Core Team","series-title":"R: A Language and Environment for Statistical Computing","key":"10.1016\/j.ejphar.2017.12.040_bib26"},{"key":"10.1016\/j.ejphar.2017.12.040_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1681\/ASN.V132359","article-title":"Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis","volume":"13","author":"Reynolds","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib28","doi-asserted-by":"crossref","first-page":"73486","DOI":"10.18632\/oncotarget.11970","article-title":"Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer","volume":"7","author":"Schinagl","year":"2016","journal-title":"Oncotarget"},{"unstructured":"Seshan V.E., 2014. clinfun: Clinical Trial Design and Data Analysis Functions. R Package Version 1.0.14. URL: \u3008http:\/\/CRAN.R-project\/package = clinfun\u3009.","key":"10.1016\/j.ejphar.2017.12.040_bib29"},{"key":"10.1016\/j.ejphar.2017.12.040_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrrheum.2010.117","article-title":"Biological therapy for lupus nephritis-tribulations and trials","volume":"6","author":"Smith","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2567.2008.02879.x","article-title":"Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells","volume":"126","author":"Stojanovi\u0107","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.ejphar.2017.12.040_bib32","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/ndt\/14.7.1658","article-title":"Development of scarring and renal failure in a rat model of crescentic glomerulonephritis","volume":"14","author":"Tam","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2017.12.040_bib33","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.4049\/jimmunol.1500572","article-title":"Selective targeting of a disease-related conformational isoform of macrophage migration inhibitory factor ameliorates inflammatory conditions","volume":"195","author":"Thiele","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2017.12.040_bib34","series-title":"Dose Finding in Drug Development","first-page":"146","author":"Ting","year":"2006"},{"key":"10.1016\/j.ejphar.2017.12.040_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03401748","article-title":"Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production","volume":"4","author":"Yang","year":"1998","journal-title":"Mol. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917308348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917308348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T22:30:59Z","timestamp":1719700259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917308348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"alternative-id":["S0014299917308348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.12.040","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.12.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}